Valuation: Intellipharmaceutics International Inc.

Market Cap 14.06L 12.56L 11.6L 10.51L 19.67L 13Cr 20L 1.4Cr 55.28L 7Cr 52.78L 51.66L 22Cr P/E 2021
-0.69x
P/E 2022 -0.82x
Enterprise Value 36.49L 32.58L 30.1L 27.28L 51.03L 35Cr 51.88L 3.62Cr 1.43Cr 18Cr 1.37Cr 1.34Cr 57Cr EV / Sales 2021
-
EV / Sales 2022 70.4x
Free-Float
98.24%
Yield 2021 *
-
Yield 2022 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0.15
5 years 0
Extreme 1.0E-6
0.3
10 years 0
Extreme 1.0E-6
33.5
Manager TitleAgeSince
Director of Finance/CFO - -
Comptroller/Controller/Auditor - 01/04/2007
Corporate Officer/Principal - 01/02/2014
Director TitleAgeSince
Director/Board Member - 01/09/2004
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 33
-2.54%+1.31%+54.27%+114.96% 1,13500Cr
-1.42%+3.23%+38.56%+74.44% 64TCr
+0.16%+0.08%+25.29%+95.23% 50TCr
-0.31%+3.09%+44.14%+64.80% 38TCr
-1.34%-0.47%+66.04%+41.00% 36TCr
-0.68%+2.65%+22.98%+50.39% 29TCr
-1.20%+3.04%+2.33%+22.86% 27TCr
-1.79%+1.57%+50.56%+59.08% 24TCr
-0.73%-0.10%+29.02%+99.67% 19TCr
Average -0.98%+1.95%+37.02%+69.16% 40.04TCr
Weighted average by Cap. -1.35%+2.66%+41.02%+79.75%

Financials

2021 2022
Net sales - 65.73T 58.7T 54.22T 49.14T 91.93T 62.4L 93.45T 7L 3L 32.69L 2L 2L 1.03Cr
Net income -51.45L -45.95L -42.45L -38.47L -71.96L -49Cr -73.15L -5.11Cr -2.02Cr -26Cr -1.93Cr -1.89Cr -81Cr -28.92L -25.83L -23.86L -21.62L -40.45L -27Cr -41.12L -2.87Cr -1.14Cr -14Cr -1.09Cr -1.06Cr -45Cr
Net Debt 11.45L 10.23L 9L 9L 16.02L 11Cr 16.29L 1.14Cr 45.02L 5.7Cr 42.99L 42.07L 18Cr 22.42L 20.02L 18.5L 16.76L 31.36L 21Cr 31.88L 2.23Cr 88.13L 11Cr 84.15L 82.36L 35Cr
Logo Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.
Employees
11
  1. Stock Market
  2. Stocks
  3. IPCIQ Stock